Analyst Price Targets — KYMR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 16, 2026 10:48 am | Joseph Catanzaro | Mizuho Securities | $140.00 | $114.12 | TheFly | Kymera Therapeutics price target raised to $140 from $120 at Mizuho |
| July 13, 2026 10:34 am | Brian Abrahams | RBC Capital | $115.00 | $119.35 | TheFly | Kymera Therapeutics downgraded to Sector Perform from Outperform at RBC Capital |
| June 29, 2026 11:22 am | Srikripa Devarakonda | Truist Financial | $136.00 | $108.12 | TheFly | Kymera Therapeutics price target raised to $136 from $116 at Truist |
| June 26, 2026 11:55 am | Edward Nash | Canaccord Genuity | $129.00 | $116.46 | TheFly | Kymera Therapeutics price target raised to $129 from $106 at Canaccord |
| June 26, 2026 10:57 am | Kalpit Patel | B.Riley Financial | $155.00 | $116.46 | StreetInsider | Kymera Therapeutics (KYMR) PT Raised to $155 at B.Riley |
| June 8, 2026 5:05 pm | Leah Rush Cann | Loop Capital Markets | $97.00 | $73.95 | StreetInsider | Kymera Therapeutics (KYMR) PT Raised to $97 at Brookline Capital Markets |
| May 6, 2026 9:22 am | Edward Nash | Canaccord Genuity | $106.00 | $82.71 | TheFly | Kymera Therapeutics initiated with a Buy at Canaccord |
| April 30, 2026 3:56 pm | Judah Frommer | Morgan Stanley | $119.00 | $80.73 | TheFly | Kymera Therapeutics price target lowered to $119 from $123 at Morgan Stanley |
| February 26, 2026 8:25 pm | Judah Frommer | Morgan Stanley | $123.00 | $95.03 | StreetInsider | Kymera Therapeutics (KYMR) PT Lowered to $123 at Morgan Stanley |
| February 26, 2026 4:56 pm | Brian Abrahams | RBC Capital | $108.00 | $91.87 | StreetInsider | Kymera Therapeutics (KYMR) PT Raised to $108 at RBC Capital |
Latest News for KYMR
NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Kymera Therapeutics, Inc. (NASDAQ: KYMR) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.
SHAREHOLDER ALERT: Purcell and Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR) PR N
NEW YORK, July 16, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Kymera Therapeutics, Inc. (NASDAQ: KYMR) on behalf of the company's shareholders. The investigation seeks to determine whether Kymera Therapeutics's directors breached their fiduciary duties in connection with recent corporate actions.
According to a Form 4, proceeds of approximately $6.0 million were realized from the exercise and immediate sale of 50,000 shares at $119.00 per share on July 7, 2026. The transaction reduced the insider's direct common stock holdings by 7%, leaving a residual direct position of 667,000 shares.
Dr. Laws, former immunology leader at Sanofi, will oversee global development of Kymera's KT-621 program KT-621 parallel Phase 2b trials advancing in AD and asthma, with data expected by year-end 2026 and late 2027, respectively; Phase 3 trials in AD planned to initiate by mid-2027 WATERTOWN, Mass.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for KYMR.
U.S. House Trading
No House trades found for KYMR.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.